These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22995972)

  • 41. Efficacy of risperidone on positive features of schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
    Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
    Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
    CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study.
    Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
    Egan MF; Zhao X; Smith A; Troyer MD; Uebele VN; Pidkorytov V; Cox K; Murphy M; Snavely D; Lines C; Michelson D
    Hum Psychopharmacol; 2013 Mar; 28(2):124-33. PubMed ID: 23532746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
    Tybura P; Mak M; Samochowiec A; Pełka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
    Psychiatr Pol; 2013; 47(4):567-78. PubMed ID: 24946464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.